Latanoprostene bunod

What is Latanoprostene bunod?

• Latanoprostene bunod (VYZULTA) is a prostaglandin analog used for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

What are the uses of this medicine?

• This medicine is used for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

How does this medicine work?

• Latanoprostene bunod is thought to lower intraocular pressure by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes.
• Intraocular pressure is a major modifiable risk factor for glaucoma progression.
• Reduction of intraocular pressure reduces risk of glaucomatous visual field loss.

Who Should Not Use this medicine ?

• This medicine have no usage limitations.

What drug interactions can this medicine cause?

• No clinically important drug interactions have been observed with VYZULTA.

Is this medicine FDA approved?

• It was approved for use in the United States in 2017.

How should this medicine be used?

Recommended Dosageː

• The recommended dosage is one drop in the conjunctival sac of the affected eye(s) once daily in the evening.

Administration

• Take one drop in the affected eye(s) once daily in the evening.
• Do not administer VYZULTA(latanoprostene bunod ophthalmic solution), 0.024% more than once daily since it has been shown that more frequent administration of prostaglandin analogs may lessen the intraocular pressure lowering effect.
• If VYZULTA is to be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure, administer each drug product at least five (5) minutes apart.

What are the dosage forms and brand names of this medicine?

This medicine is available in fallowing doasage form:

• As Topical ophthalmic solution: 0.24 mg/mL latanoprostene bunod (0.024%)

This medicine is available in fallowing brand namesː

• VYZULTA

What side effects can this medication cause?

The most common side effects of this medicine include:

• conjunctival hyperemia
• eye irritation
• eye pain
• instillation site pain

What special precautions should I follow?

• VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% may cause changes to pigmented tissues. Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent.
• VYZULTA may gradually change eyelashes and vellus hair in the treated eye. These changes include increased length, thickness, and the number of lashes or hairs. Eyelash changes are usually reversible upon discontinuation of treatment.
• VYZULTA should be used with caution in patients with a history of intraocular inflammation (iritis/uveitis) and should generally not be used in patients with active intraocular inflammation.
• Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to avoid contamination of the solution by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.
• Contact lenses should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of VYZULTA.
• Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs.
• There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products.

What to do in case of emergency/overdose?

• In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.

• Overdose related information is also available online at poisonhelp.org/help.
• In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.

Can this medicine be used in pregnancy?

• There are no available human data for the use of VYZULTA during pregnancy to inform any drug associated risks.

Can this medicine be used in children?

• Use in pediatric patients aged 16 years and younger is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.

What are the active and inactive ingredients in this medicine?

Active ingredient:

• LATANOPROSTENE BUNOD

Inactive ingredients:

• BENZALKONIUM CHLORIDE
• POLYSORBATE 80
• GLYCERIN
• EDETATE SODIUM
• WATER

Who manufactures and distributes this medicine?

Packager: Bausch & Lomb Incorporated

What should I know about storage and disposal of this medication?

• Unopened bottle should be stored refrigerated at 2º to 8ºC (36º to 46ºF).
• Once a bottle is opened it may be stored at 2º to 25ºC (36º to 77ºF) for 8 weeks.
• During shipment, bottles may be maintained at temperatures up to 40°C (104°F) for a period not exceeding 14 days.
• Protect from light.
• Protect from freezing.

• Dailymed label info on Latanoprostene bunod
• FDA Latanoprostene bunod

Latanoprostene bunod Resources
Latest articles Most recent articles Ongoing trials	Wikipedia